Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma

Deshui Yu; Xuanzhi Zhang; Lixia Gao; Subo Qian; Hong Tang; Ning Shao

doi:10.3389/fonc.2022.924072

Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma

Front Oncol. 2022 Sep 28:12:924072. doi: 10.3389/fonc.2022.924072. eCollection 2022.

Authors

Deshui Yu¹, Xuanzhi Zhang², Lixia Gao³, Subo Qian⁴, Hong Tang⁵, Ning Shao⁴

Affiliations

¹ Department of Urology, Second People's Hospital of Wuxi Affiliated to Nanjing Medical University, Wuxi, China.
² Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
³ Department of Operation Room, Second People's Hospital of Wuxi Affiliated to Nanjing Medical University, Wuxi, China.
⁴ Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
⁵ Department of Pathology, The Affiliated WuXi No.2 People's Hospital of Nanjing Medical University, Wuxi, China.

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic tumor. The purpose of the present study was to establish a novel immunotype for different immune infiltration and overall survival (OS) of patients with ccRCC.

Methods: Based on the Cancer Genome Atlas Project (TCGA) database (discovery set), a novel immunotype was established using ssGSEA methods. The databases of Fudan University Shanghai Cancer Center (FUSCC) and Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine (XHH) served as an external validation set. GSEA was carried out to identify the immunotype associated signal transduction pathways.

Results: A total of 652 ccRCC patients were included in our study. We constructed a novel immunotype of ccRCC to classify patients into three groups: high-immunity, moderate-immunity, and low-immunity. The high-immunity and moderate-immunity groups had higher ImmuneScores, ESTIMATEScores, StromalScores, and lower tumor purity than that of the low-immunity group in both sets. Additionally, the patients from the high-immunity and moderate-immunity groups had longer survival than patients from low-immunity group in both discovery set and validation set (HR = 2.54, 95% CI: 1.56-4.13, p < 0.01; HR = 2.75, 95% CI: 1.24-6.11, p = 0.01).

Conclusion: In summary, we defined a novel immunotype of ccRCC. The immune types could be used as a clinical predictive tool to identify ccRCC patients with different survival. In addition, the immune-related biological signaling pathway also brought new insights on the mechanism of ccRCC.

Keywords: PD-1; PD-L1; ccRCC; immunotype; overall survival.